This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
July 03, 2020
Vicore Pharma has completed a directed share issue of SEK 185 million
July 02, 2020
Vicore Pharma intends to carry out a directed share issue
July 02, 2020
GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020
July 02, 2020
Invitation to attend a teleconference on July 2, 1.30 pm CET – DTx US commercialization plan
July 02, 2020
Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance
July 01, 2020
Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
June 30, 2020
Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO
June 30, 2020
Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal
June 30, 2020
Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients
June 30, 2020
Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population